MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, has announced the pricing of an underwritten public offering of 4,925,000 shares of its common stock at a public offering price of $51.00 per share, before underwriting discounts, as detailed in the press release
MyoKardia Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, has announced the pricing of an underwritten public offering of 4,925,000 shares of its common stock at a public offering price of $51.00 per share, before underwriting discounts, as detailed in the press release. In addition, the underwriters have a 30-day option to purchase up to an additional 738,750 shares of common stock on the same terms and conditions.
Latham & Watkins LLP represents the underwriters in the offering with a corporate deal team led by Silicon Valley partner Brian Cuneoand Orange County partner Shayne Kennedy with Silicon Valley associates Miles Jennings, Lauren Schneider and Raul Gonzalez. Advice was also provided by Silicon Valley partner Christopher Hazuka with associate Peggy Ni on intellectual property matters; by Washington, D.C. partner John Manthei with associates Robert Canning and Chad Jennings on FDA regulatory matters; and by San Francisco partner Grace Lee with Silicon Valley associate Mi Zhou on tax matters.
